On May 24, 2022 Affimed N.V. (Nasdaq: AFMD) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, reported that it will release first quarter 2022 results and corporate update on Wednesday, June 1, 2022 (Press release, Affimed, MAY 24, 2022, View Source [SID1234614989]). The Company will host a conference call at 8:30 a.m. Eastern Daylight Time. The conference call will be available via phone and webcast. To access the call, please dial +1 (409) 220-9054 for U.S. callers, or +44 (0) 8000 323836 for international callers, and reference conference ID 4440407 approximately 15 minutes prior to the call. To access the live audio webcast of the conference call please visit the "Investors" section of the Company’s website at View Source A replay of the call will be archived on Affimed’s website for 30 days after the call.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!